IL106743A - Tablets with improved bioavailability of the active material clodronic acid - Google Patents
Tablets with improved bioavailability of the active material clodronic acidInfo
- Publication number
- IL106743A IL106743A IL10674393A IL10674393A IL106743A IL 106743 A IL106743 A IL 106743A IL 10674393 A IL10674393 A IL 10674393A IL 10674393 A IL10674393 A IL 10674393A IL 106743 A IL106743 A IL 106743A
- Authority
- IL
- Israel
- Prior art keywords
- tablet
- tablets
- weight
- content
- active material
- Prior art date
Links
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 229960002286 clodronic acid Drugs 0.000 title claims abstract description 34
- 239000011149 active material Substances 0.000 title description 46
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract 7
- 239000011734 sodium Substances 0.000 claims description 16
- 229910052708 sodium Inorganic materials 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 13
- 239000000454 talc Substances 0.000 claims description 13
- 229910052623 talc Inorganic materials 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 229920002261 Corn starch Polymers 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 150000004685 tetrahydrates Chemical class 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims 5
- 239000000945 filler Substances 0.000 claims 4
- 229920002472 Starch Polymers 0.000 claims 2
- 239000008120 corn starch Substances 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 235000012222 talc Nutrition 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 25
- 239000002775 capsule Substances 0.000 description 18
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000001913 cellulose Substances 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 235000019759 Maize starch Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 6
- XWHPUCFOTRBMGS-UHFFFAOYSA-L disodium clodronate tetrahydrate Chemical compound O.O.O.O.[Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O XWHPUCFOTRBMGS-UHFFFAOYSA-L 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical class OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 3
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 235000009973 maize Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- -1 salt tetrahydrate Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000000359 Triticum dicoccon Species 0.000 description 1
- CPGKMLVTFNUAHL-UHFFFAOYSA-N [Ca].[Ca] Chemical compound [Ca].[Ca] CPGKMLVTFNUAHL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229960000579 clodronate disodium Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE9307393U DE9307393U1 (de) | 1993-05-15 | 1993-05-15 | Tablette mit verbesserter Bioverfügbarkeit, enthaltend Dichlormethylendiphosphonsäure als Wirkstoff |
| DE19934322057 DE4322057A1 (de) | 1993-07-02 | 1993-07-02 | Tablette mit verbesserter Bioverfügbarkeit enthaltend Dichlormethylendiphosphonsäure als Wirkstoff |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL106743A0 IL106743A0 (en) | 1993-12-08 |
| IL106743A true IL106743A (en) | 1999-11-30 |
Family
ID=25927331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10674393A IL106743A (en) | 1993-05-15 | 1993-08-19 | Tablets with improved bioavailability of the active material clodronic acid |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5650168A (cs) |
| EP (2) | EP0697890A1 (cs) |
| JP (1) | JP3699110B2 (cs) |
| KR (1) | KR100263284B1 (cs) |
| CN (1) | CN1041797C (cs) |
| AT (2) | ATE128363T1 (cs) |
| AU (1) | AU687744B2 (cs) |
| BR (1) | BR9307859A (cs) |
| CA (1) | CA2162470C (cs) |
| CZ (1) | CZ287984B6 (cs) |
| DE (1) | DE59300688D1 (cs) |
| DK (1) | DK0625355T5 (cs) |
| ES (1) | ES2065313T5 (cs) |
| FI (1) | FI111519B (cs) |
| GR (2) | GR940300095T1 (cs) |
| HU (1) | HU220872B1 (cs) |
| IL (1) | IL106743A (cs) |
| NO (1) | NO307548B1 (cs) |
| NZ (1) | NZ254765A (cs) |
| PL (1) | PL173026B1 (cs) |
| RU (1) | RU2134103C1 (cs) |
| SK (1) | SK281193B6 (cs) |
| TW (1) | TW350772B (cs) |
| UA (1) | UA39884C2 (cs) |
| WO (1) | WO1994026310A1 (cs) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94926C (fi) | 1993-11-12 | 1995-11-27 | Leiras Oy | Menetelmä klodronaattivalmisteen valmistamiseksi |
| DE19615812A1 (de) * | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
| DE19719680A1 (de) | 1997-05-09 | 1998-11-19 | Boehringer Mannheim Gmbh | Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz |
| FI109088B (fi) * | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| EP0998932A1 (de) | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung |
| SE9901272D0 (sv) * | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
| CZ20002567A3 (cs) * | 2000-07-11 | 2001-12-12 | Léčiva, A.S. | Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby |
| RU2192848C1 (ru) * | 2001-10-30 | 2002-11-20 | Закрытое акционерное общество "ВЕРОФАРМ" | Противорвотное средство |
| EA013106B1 (ru) * | 2003-09-19 | 2010-02-26 | Сан Фарма Адвансед Ресьорч Компани Лтд. | Оральная система доставки лекарственного препарата (варианты) |
| US10213387B2 (en) | 2003-09-19 | 2019-02-26 | Sun Pharma Advanced Research Company Ltd. | Oral drug delivery system |
| US10226428B2 (en) | 2003-09-19 | 2019-03-12 | Sun Pharma Advanced Research Company Ltd. | Oral drug delivery system |
| US7151400B2 (en) * | 2004-07-13 | 2006-12-19 | Taiwan Semiconductor Manufacturing Company, Ltd. | Boost-biased level shifter |
| CN100370972C (zh) * | 2006-01-10 | 2008-02-27 | 北京申科联华科技有限公司 | 一种具有益气养阴、活血复脉功效的片剂及制备方法 |
| WO2009017222A1 (ja) * | 2007-08-02 | 2009-02-05 | Teijin Pharma Limited | 骨代謝異常に起因する疾患の予防剤又は治療剤 |
| MX2010008861A (es) * | 2008-02-15 | 2011-02-22 | Sun Pharma Advanced Res Co Ltd | Tableta oral de liberacion controlada con efecto de liberacion masiva reducido. |
| CN118370733B (zh) * | 2024-06-21 | 2024-10-01 | 山东新时代药业有限公司 | 一种钙代谢调节药物氯膦酸二钠片及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH9776A (en) * | 1967-12-11 | 1976-03-17 | M Francis | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use |
| DE2813121A1 (de) * | 1977-03-29 | 1978-10-12 | Procter & Gamble | Verwendung von dichlormethan-diphosphonatverbindungen bei der bekaempfung von collagen-erkrankungen und zur wundheilung |
| US4634691A (en) * | 1980-10-07 | 1987-01-06 | The Procter & Gamble Company | Method for inhibiting tumor metastasis |
| US4517179A (en) * | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
| SU1437023A1 (ru) * | 1986-01-02 | 1988-11-15 | Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств | Антацидное средство "Кальмагин |
| SE457326B (sv) * | 1986-02-14 | 1988-12-19 | Lejus Medical Ab | Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa |
| ES2040733T3 (es) * | 1986-12-20 | 1993-11-01 | Boehringer Mannheim Gmbh | Medicamentos que contienen clodronato y procedimiento para su preparacion. |
| DE3804686A1 (de) * | 1988-02-15 | 1989-08-24 | Henkel Kgaa | Arzneimittel mit einer kombination von cytostatika bzw. hormontherapeutika und phosphonoderivaten |
| FR2629716B1 (fr) * | 1988-04-07 | 1991-07-19 | Sanofi Sa | Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique |
| FI83421C (fi) † | 1989-06-21 | 1991-07-10 | Huhtamaeki Oy | Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat. |
| HU215124B (hu) * | 1991-02-26 | 1998-09-28 | Norwich Eaton Pharmaceuticals, Inc. | Eljárás csontritkulás (osteoporosis) kezelésére szolgáló ösztrogént és difoszfonátot tartalmazó, szinergetikus hatású gyógyszerkészítmények előállítására |
| SE501389C2 (sv) * | 1992-04-24 | 1995-01-30 | Leiras Oy | Farmaceutiskt preparat och förfarande för dess framställning |
| JPH08505142A (ja) * | 1992-12-23 | 1996-06-04 | メルク エンド カンパニー インコーポレーテッド | 骨損失を治療及び予防するためのビスホスホネート／エストロゲン療法 |
-
1993
- 1993-07-24 CA CA002162470A patent/CA2162470C/en not_active Expired - Lifetime
- 1993-07-24 UA UA95114854A patent/UA39884C2/uk unknown
- 1993-07-24 ES ES93111827T patent/ES2065313T5/es not_active Expired - Lifetime
- 1993-07-24 AU AU47020/93A patent/AU687744B2/en not_active Expired
- 1993-07-24 DK DK93111827T patent/DK0625355T5/da active
- 1993-07-24 EP EP93917636A patent/EP0697890A1/de not_active Withdrawn
- 1993-07-24 WO PCT/EP1993/001967 patent/WO1994026310A1/de not_active Application Discontinuation
- 1993-07-24 BR BR9307859A patent/BR9307859A/pt not_active Application Discontinuation
- 1993-07-24 NZ NZ254765A patent/NZ254765A/en not_active IP Right Cessation
- 1993-07-24 PL PL93307133A patent/PL173026B1/pl unknown
- 1993-07-24 JP JP51843194A patent/JP3699110B2/ja not_active Expired - Fee Related
- 1993-07-24 AT AT93111827T patent/ATE128363T1/de active
- 1993-07-24 CZ CZ1995100A patent/CZ287984B6/cs not_active IP Right Cessation
- 1993-07-24 DE DE59300688T patent/DE59300688D1/de not_active Expired - Lifetime
- 1993-07-24 HU HU9403160A patent/HU220872B1/hu unknown
- 1993-07-24 EP EP93111827A patent/EP0625355B2/de not_active Expired - Lifetime
- 1993-07-24 RU RU95121748A patent/RU2134103C1/ru active
- 1993-07-24 KR KR1019950705094A patent/KR100263284B1/ko not_active Expired - Lifetime
- 1993-07-24 US US08/537,853 patent/US5650168A/en not_active Expired - Lifetime
- 1993-07-24 SK SK48-95A patent/SK281193B6/sk not_active IP Right Cessation
- 1993-08-19 IL IL10674393A patent/IL106743A/en not_active IP Right Cessation
- 1993-09-10 TW TW082106635A patent/TW350772B/zh not_active IP Right Cessation
- 1993-09-23 CN CN93118149A patent/CN1041797C/zh not_active Expired - Lifetime
-
1994
- 1994-05-13 AT AT0007494U patent/AT128U1/de not_active IP Right Cessation
- 1994-11-11 FI FI945313A patent/FI111519B/fi not_active IP Right Cessation
- 1994-11-17 NO NO944405A patent/NO307548B1/no not_active IP Right Cessation
-
1995
- 1995-01-31 GR GR940300095T patent/GR940300095T1/el unknown
- 1995-09-28 GR GR950402574T patent/GR3017547T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110177168A1 (en) | Composition | |
| US9827197B2 (en) | Diclofenac formulations and methods of use | |
| FI117373B (fi) | Parasetamolia ja domperidonia sisältävä kalvopäällysteinen tabletti | |
| IL106743A (en) | Tablets with improved bioavailability of the active material clodronic acid | |
| HU227759B1 (en) | Improved pharmaceutical formulations containing ibuprofen and codeine | |
| JP2893307B2 (ja) | ニコランジルの製薬的に安定な製剤 | |
| UA52682C2 (uk) | Таблетка малеату тримебутину в оболонці | |
| CY1653A (en) | Pharmaceutical compositions with analgesic properties and the preparation and use thereof | |
| WO2002058666A2 (en) | Process for preparing non-hygroscopic sodium valproate composition | |
| JPS5940134B2 (ja) | 抗血栓性医薬組成物 | |
| IL139407A (en) | Oral preparations containing -8 chloro-6, 11 - dihydro-11 - (-4-piperidaldehyde) - H5-benzo [5, 6] cyclohepta [1, -2 [b-pyridine | |
| AU756338B2 (en) | Stabile compositions comprising levosimendan and alginic acid | |
| GB2336999A (en) | High-dosage triclosan compositions | |
| WO2019014201A1 (en) | MOLINDONE COMPOSITIONS WITH EXTENDED RELEASE | |
| US3842169A (en) | Composition and method for treatment of pathological calcification in animals | |
| HK136097A (en) | Tablet with improved bioavailability containing dichloromethylenediphosphonic acid as active ingredient | |
| RU2106141C1 (ru) | Способ получения лекарственной формы ненаркотического анальгетика | |
| AU2002241960A1 (en) | Process for preparing non-hygroscopic sodium valproate composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |